相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Yeon Hee Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
S. M. Tovey et al.
BRITISH JOURNAL OF CANCER (2009)
Refining Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
Giuseppe Curigliano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
Marc Spielmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller
Ana M. Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M. Untch et al.
ANNALS OF ONCOLOGY (2008)
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma
Emer O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)
E. O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
M Colleoni et al.
ANNALS OF ONCOLOGY (2004)
分享论文
